• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Ulixertinib

Product ID U451349
Cas No. 869886-67-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $136.40 In stock
25 mg $238.60 In stock
100 mg $817.70 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Ulixertinib is an ERK1/2 inhibitor that has been found to impair proliferation, arrest cell cycle, and induce apoptosis in lymphoma cell lines. Ulixertinib has also demonstrated effectiveness in several models that show either intrinsic or acquired resistance to MAPK pathway inhibitors.

Product Info

Cas No.

869886-67-9

Purity

≥98%

Formula

C21H22Cl2N4O2

Formula Wt.

433.33

Synonym

BVD-523, VRT752271

Solubility

DMSO:86 mg/mL (198.46 mM) Ethanol:15 mg/mL (34.61 mM) Water:Insoluble

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

U451349 MSDS PDF

Info Sheet

U451349 Info Sheet PDF

References

Ding WJ, Tao WP, Zeng T, et al. Selective ERK inhibitor ulixertinib inhibits proliferation and induces apoptosis in lymphoma cell lines. Int J Clin Exp Med. 2017;9(6):10955-10962.

Germann U, Furey B, Roix J, et al. The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only